Providers

Dr Basquille has been a consultant since 2000 in General Adult Psychiatry with a specialism in Substance Misuse practising in the NHS in charge of a busy Assessment and Treatment Service, a University Hospital Liaison Service and an Alcohol Clinic.

He practises privately at the Capio Nightingale Hospital London and Harley Street.

Dr Wasan is a Consultant Cardiologist managing all aspects of cardiovascular disease.

He specialises in all aspects of ischaemic heart disease. This includes screening & prevention in high risk patients, investigating patients with symptoms of coronary artery disease & the subsequent diagnosis and management. This includes the opening of narrowed or blocked arteries through the radial or femoral artery (percutaneous angioplasty). He also implants permanent pacemakers.

Dr Wasan studied medicine at Imperial College in London. His cardiology training was in the North West Thames region. He accredited as a Cardiologist in 2005 & was appointed as a Consultant Cardiologist at the Queen Elizabeth (now part of South London Healthcare) & St Thomas' Hospitals.

Dr Wasan has undertaken research in the changes in cardiac function after angioplasty & bypass surgery & is an author on a number of original publications arising from this work.

Dr Wasan is also co-author on peer-reviewed papers on cardiac function, echocardiography, arrhythmias and hypertension.

Colin Natali is a consultant spinal, trauma and general orthopaedic surgeon, appointed to St Bartholomews and The Royal London Hospital, Whitechapel in December 1996.

He is also programme director for the orthopaedic training programme, and the lead for undergraduate training at the hospital.

Colin has admitting rights at The Lister, Bupa Cromwell, the London Independent Hospital, and the London Bridge Hospital, for his private practice.

He founded back2normal in 2001 alongside TJ Salih, and recently formed a spinal consortium called All About Spines, and a healthcare design company called London medical Design.

Anthony Dorling qualified in Medicine from the University of London in 1987, did general medical training in hospitals around the South East of England and gained membership of the Royal College of Physicians in 1990.

He did his PhD under the supervision of Robert Lechler at the Royal Postgraduate Medical School, before embarking on specialist training in Nephrology in 1995.

He was appointed Senior Lecturer in Immunology at Imperial College London and honorary Consultant Nephrologist at the Hammersmith Hospital in 2001, becoming a Reader in 2005.

He was awarded fellowship of the Royal College of Physicians in the same year. He took up his current post in October 2009.

Richard Lane is Ambassador and Immediate Past President of Diabetes UK, the UK's leading diabetes charity.

Richard, who has Type 1 diabetes, was one of the first people in the UK to receive islet cell transplants in 2005.

The surgery came after a long history of diabetes-related complications, including comas and severe hypoglycaemic episodes (hypos).

The transplants transformed Richard’s life and he has not had a serious hypo since his first operation.

He was the first person in the UK to completely come off insulin. This situation continued for about a year, but he had then to go back on to insulin. He contracted a viral infection from which some antibodies developed which were damaging his new beta cells, and now he has to supplement his natural insulin via the pump and count carbs again.

Richard, who formerly held the position of President at Diabetes UK, has been a great advocate for the charity. He has spent much of his free time travelling the country undertaking public speaking at local community meetings and conferences to raise awareness of the condition and the work of Diabetes UK.

Professor Sehouli is a gynaecological oncologist, working at the Charité, University of Medicine in Berlin, Germany.

Professor Jalid Sehouli is currently the director of the department of gynecology in the famous Charité/ Campus Virchow-Klinikum and Campus Benjamin Franklin. He is also the head of the European Competence Center for Ovarian Cancer and is leading the gynaecological oncology at all three Campi at Charité Medical University in Berlin.

Professor Sehouli founded the German Foundation for ovarian cancer patients, being involved in many initiatives for patients.

Together with Professor Lichtenegger he founded the German north eastern society for gynaecological oncology (NOGGO). In 2000 he initiated the tumor bank ovarian cancer, which became the largest biobank for fresh frozen tissue worldwide.

Since 2013 Professor Sehouli was nominated as speaker for the OVAR Kommission of the AGO, Germany.

His clinical and scientific interest focuses on the surgical therapy and systemic treatment of advanced gynaecological malignancies. He lead several preclinical trials in predicting the surgical outcome. He is principle investigator in many Phase I to Phase III clinical trials in ovarian cancer.

He has published more than 250 national and international papers in the field of gynaecologic oncology.
He is a member of the executive board of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), and a member of the European Society of Gynaecological Oncology (ESGO), the Gynaecologic Cancer Intergroup (GCIG), the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC).

Charlie Gourley graduated with honours in Genetics from the University of Glasgow in 1991. He then went on to qualify as a medical doctor in 1994 also at the University of Glasgow.

Charlie progressed through his medical training in Edinburgh, continuously combining that with active research interests. He has successfully held research positions both at the University of Edinburgh and within the NHS.

Charlie’s career ladder took him to his current position as a Professor and Honorary Consultant in Medical Oncology, specialising in gynaecological cancers. He leads a clinical research team at the Edinburgh Cancer Centre, and a translational research group at the University of Edinburgh Cancer Research UK Centre.

He is a member of the National Cancer Research Network gynaecological cancers clinical studies group, the National Cancer Research Network ovarian subgroup and the Scottish Gynaecological Cancers Trials Group. He is also an active member of several other committees.

Elena Ioana Braicu is a senior gynecologist at the Department for Gynecology Campus Vrchow, Charité Medical University Berlin. She is leading the translational research within this department, and coordinating the Tumor Bank for Ovarian Cancer network (www.toc-network.de).

She qualified in medicine in 2003 from “Iuliu Hatieganu” Medical University in Cluj-Napoca, Romania. She was research fellow at Max Delbrück Research center Berlin in 2003 and 2004, than at the Charité from 2005 and 2006 and at the University of Basel in 2008. Since 2009 she is working at the European Competence Center for Ovarian Cancer at the Charité Medical University.

She is representing the translational group of NOGGO, north eastern German society for gynecological oncology within ENGOT. She is a founding EUTROC member and is leading the working group for biobanking. She is also consultant for pediatric gynecology at the Charité Medical University.

Dr. Braicu participated in several European projects, like OVCAD (www.ovcad.eu) and OCTIPS (www.octips.eu). She is work package leader for biobanking and data repository in the Fp7 European Phase I/II clinical study, Gannet53 (www.gannet53.eu).

She is member in several national and international study groups (e.g. AGO, NOGGO, TOC, ENGOT, EUTROC, GCIG). She is member of the German Foundation of Ovarian Cancer.

Furthermore she is participating in several Phase I to Phase III clinical study as sub-investigator. She is the vice-coordinator of the clinical trial study center at the Charité Medical University.

Since 2013, she is a fellow of the clinical scientist program of the Charité Universitätsmedizin Berlin and the Berlin Institute of Health.

Her main interests are prevention and diagnostic of pelvic tumors in general and high risk population. She is focusing also in the discovery of predictive biomarkers for clinical outcome in ovarian cancer patients.

Christina Fotopoulou trained in obstetrics and gynecology and subspecialized in gynaecological oncology at the Charité University Hospital of Berlin in both the surgical and systemic treatment of women with advanced gynaecological malignancies and completed her PhD thesis entitled “Current Aspects in the Operative Treatment of Epithelial Ovarian Cancer”.

She is currently a Consultant Gynecological Oncologist and Adjunct Professor in the Imperial College London Healthcare Trust in Queen Charlottes Hospital in London and Ovarian Cancer Action Research center.

She has been the leading consultant and Vice Director of the Clinic for Gynecology at the Charité in Berlin, one of the largest reference and accredited centers for gynecological cancer in Germany, as well the Principal Coordinator of the European Competence Center for Ovarian Cancer, which was created in 2007 in Berlin.

Her principal area of clinical practice is in exenterative procedures for advanced forms of pelvic malignancies and in the cytoreductive debulking of primary or relapsed ovarian cancer. Furthermore, she was trained in the reconstructive surgery of oncologic patients after extensive exenterations.

Her area of research is the creation and validation of scores for optimal surgical quality, the analysis of tumour dissemination patterns, histopathological characteristics and surgical outcome in primary and relapsed of ovarian cancer and in the quality of life of patients after extensive operative procedures.

Christina Fotopoulou is a member of the German AGO- Ovarian Cancer Steering Group which is responsible for the generation of national guidelines for the management of ovarian cancer and borderline ovarian lesions. She is the surgical lead in the European Network for Translational Research in Ovarian Cancer (EUTROC) in the working package “Predicting surgical outcome”.

She has broad experience in national and international clinical and surgical trials in Germany and in innovative intraperitoneal immunotherapies in palliative stages of gynaecological malignancies.

She has lectured in many countries on her clinical research and surgical experience.

She is on the editorial board of two journals and reviewer in numerous international gynaecological and oncological journals and is member of various international oncological committees, including ASCO, ESGO, IGCS, ESMO, ENGOT, AGO and NOGGO.

EUTROC (European Translational Research network in Ovarian Cancer) is a European cancer network addressing the fragmentation currently hindering translational research for cutting edge therapies in ovarian cancer.

It will strengthen European excellence in the diagnosis and treatment of OC.

The need to bring promising drug candidates and treatments into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, lack of suitable ovarian cancer models, lack of validated predictive biomarker diagnostics, and integrated appropriate management of translational research partners (including pharma and biotech companies).

Developing effective diagnostic and treatment strategies require structured joint efforts of experts on tumor immunology, epigenetics, pathology, bioinformatics, drug development and delivery, trial development, clinical oncology and gynecological oncology.

Leading European researchers and clinicians together with the pharmaceutical industry and biotech companies will focus on preclinical and clinical studies in ovarian cancer. Therefore new targets will be identified, validated and translated to new drugs and brought to clinical practice. Standardisation and harmonisation of laboratory practices and good clinical practice procedures will BE performed within the consortium.

The consortium combines expertise in clinical as well as preclinical research. Involved researchers are coordinating a number of investigator-initiated Phase I, II trials.The Network will build a platform for research and strong educational programs for the next generation of experts aimed at developing individualised patients benefit.